Introduction
Materials and methods
Date sources and searches
Study selection
Data extraction and quality assessment
Data synthesis and analysis
Results
Study comparisons, populations, and format
Study characteristics | Number of studies |
---|---|
Thromboprophylaxis compared
| |
Low-molecular-weight heparin versus placebo | 5 |
Low-molecular-weight heparin versus unfractionated heparin | 12 |
Low-molecular-weight heparin versus warfarin | 8 |
Low-molecular-weight heparin versus fondaparinux | 11 |
Other | 7 |
Patient population
| |
Orthopedic surgery | 26 |
Other surgical | 5 |
Medical | 8 |
Funding
| |
Industry | 25 |
Other or unknown | 14 |
Geographic perspective
| |
US | 18 |
UK | 6 |
Continental Europe | 11 |
Canada | 4 |
Article | Interventions compared | Patient group | Were the outcomes accurately measured? | Were the costs accurately measured? | Was uncertainty in analysis determined? | Were estimates and costs related to the baseline risk in treatment population? |
---|---|---|---|---|---|---|
Pechevis, 2000 | Enoxaparin 40 mg daily versus placebo for 6-14 days | Medical | Yes; outcomes taken from RCTs | Yes; data from literature | Yes | Yes |
Lloyd, 2001 | UFH 5,000 units twice daily versus enoxaparin 40 mg daily for 6-14 days | Medical | Yes; outcomes taken from RCTs | Yes; data from literature | Yes | Yes |
Lamy, 2002 | Enoxaparin 20 mg versus 40 mg versus placebo for 6-14 days | Medical | Yes; outcomes taken from RCTs | Yes; data from hospital, OHIP | Yes | Yes |
Offord, 2003 | Enoxaparin 40 mg daily versus UFH 5,000 units twice daily versus none for 6-14 days | Medical | Yes; outcomes taken from RCT/meta-analysis | Yes; data from a hospital | Yes | Yes |
Schadlich, 2006 | Enoxaparin 40 mg versus UFH 5,000 units three times daily for 6-14 days | Medical | Yes; outcomes taken from RCTs/meta-analysis | Yes; data from the German Health System | Yes | Yes |
Drummond, 1994 | UFH 5,000 units 3 times daily versus enoxaparin 40 mg daily for 7 days | HFS | Yes; outcomes taken from RCTs | Yes; data from literature | Yes | Yes |
Hawkins, 1997 | Enoxaparin 30 mg daily versus UFH 5,000 units for 7 days | THR | Yes; outcomes taken from RCTs | Yes; data from literature | Yes | Yes |
Marchetti, 1999 | UFH 5,000 units twice daily versus LMWH enoxaparin 40 mg daily for 14 days | THR | Yes; outcomes taken from RCTs/meta-analysis | Yes; data from literature | Yes | Yes |
McGarry, 2004 | UFH 5,000 units twice daily versus enoxaparin 40 mg daily versus nothing for 30 days | Medical | Yes; outcomes taken from RCTs/meta-analysis | Yes; data from literature | Yes | Yes |
Deitelzweig, 2008 | UFH 5,000 units twice daily versus enoxaparin 40 mg daily versus nothing for 5 days | Medical | Yes; outcomes taken from RCTs | Yes; data from literature | Yes | Yes |
Wade, 2008 | UFH 5,000 units 3 times daily versus dalteparin 5,000 units daily for 10 days | Gynecology oncology surgery | Yes; outcomes taken from RCTs | Yes; data from literature | Yes | Yes |
Lloyd, 1997 | UFH 5,000 units twice daily/3 times daily versus nadroparin for 10-14 days | Orthopedic and general surgery | Yes; outcomes taken from meta-analysis | Yes; data from published rates of pay, costs from a hospital | Yes | Yes |
Heerey, 2005 | Dalteparin 2,500 units versus 5,000 units versus UFH for 10 days | Abdominal surgery | Yes; outcomes taken from RCTs | Yes; data from Medicare reimbursement | Yes | Yes |
O'Brien, 1994 | Enoxaparin 30 mg twice daily versus warfarin for 7 days | THR | Yes; outcomes taken from RCTs | Yes; data from literature | Yes | Yes |
Menzin, 1995 | Enoxaparin 30 mg twice daily versus warfarin (INR 2-3) versus nothing for 5-14 days | THR | Yes; outcomes taken from RCTs | Yes; data from literature | Yes | Yes |
Hull, 1997 | Warfarin versus tinzaparin 175 units/kg for 14 days | THR, TKR | Yes; outcomes taken from RCTs | Yes; data from literature | Yes | Yes |
Hawkins, 1998 | Enoxaparin 30 mg twice daily versus warfarin for 10 days | TKR | Yes; outcomes taken from RCTs | Yes; data from literature | Yes | Yes |
Francis, 1999 | Dalteparin 2,500 units, then 5,000 units versus warfarin for 10 days | THR | Yes; outcomes taken from RCTs | Yes; costs from participating hospitals in RCT | Yes; for costs | Yes |
Botteman, 2002 | Enoxaparin 30 mg daily versus warfarin 5 mg daily for 7 days | THR | Yes; outcomes taken from RCTs | Yes; data from literature | Yes | Yes |
Caprini, 2002 | Enoxaparin 30 mg twice daily for 7 days versus UFH 5,000 units 3 times daily and warfarin for 10 days | THR | Yes; outcomes taken from RCTs | Yes; data from literature | Yes | Yes |
Levin, 2001 | Desirudin 15 mg twice daily versus enoxaparin 40 mg daily for 10 days | THR | Yes; outcomes taken from RCTs | Yes; data from literature | Yes | Yes |
Honorato, 2004 | Bemiparin 3,500 units daily versus enoxaparin 40 mg daily for 8-12 days | TKR | Yes; outcomes taken from RCTs | Yes; data from National Health Care Institute, pharmacists association | Yes | Yes |
Attanasio, 2001 | Dermatan sulfate 300 mg daily versus UFH 5,000 units 3 times daily for 7 days | Surgical oncology | Yes; outcomes taken from RCTs | Yes - data from hospital costs | Yes | Yes |
Wade, 2001 | Tinzaparin 3,500 units versus enoxaparin 30 mg twice daily for 8 weeks | Spinal cord injury | Yes; outcomes taken from RCTs | Yes; data from different hospitals, DRG | Yes | Yes |
Were estimates and costs related to the baseline risk in treatment population- are these results generalizable?
| ||||||
Gordois, 2003 | Enoxaparin 40 mg daily versus fondaparinux 2.5 mg daily for 5-9 days | THR, HFS | Yes; outcomes taken from RCTs | Yes; data from NICE | Yes | Yes |
Lundkvist, 2003 | Fondaparinux 2.5 mg daily versus enoxaparin 40 mg daily for 7 days | THR, HFS | Yes; outcomes taken from RCTs | Yes; data from literature | Yes | Yes |
Wade, 2003 | Fondaparinux 2.5 mg daily versus enoxaparin 40 mg daily versus 30 mg twice daily for 7-10 days | HFS | Yes; outcomes taken from RCTs | Yes; data from literature | Yes | Yes |
Szucs, 2003 | Fondaparinux 2.5 mg daily versus enoxaparin 40 mg daily for 7 days | THR, TKR HFS | Yes; outcomes taken from RCTs | Yes; data from literature and surveys in Switzerland | Yes | Yes |
Sullivan, 2004 | Fondaparinux 2.5 mg daily versus enoxaparin 40 mg daily for 7 days | THR, TKR HFS | Yes; outcomes taken from RCTs | Yes; costs from review of 220 acute care hospitals | Yes | Yes |
Dranitsaris, 2004 | Fondaparinux 2.5 mg daily versus enoxaparin 40 mg daily for 7 days | THR, HFS | Yes; outcomes taken from a meta-analysis | Data from CIHI, surveys | Yes | Yes |
Spruill, 2004 | Fondaparinux 2.5 mg daily versus enoxaparin 30 mg twice daily for 4-5 days | TKA | Yes; outcomes taken from RCTs | Yes; data from literature | Yes | Yes |
Spruill, 2004 | Fondaparinux 2.5 mg daily versus enoxaparin 30 mg twice daily for 10 days | THR | Yes; outcomes taken from RCTs | Yes; data from literature | Yes | Yes |
Wade, 2004 | Fondaparinux 2.5 mg daily versus enoxaparin 40 mg daily for 7 days | HFS | Yes; outcomes taken from RCTs | Yes; data from literature | Yes | Yes |
Bjorvatn, 2005 | Fondaparinux 2.5 mg daily versus enoxaparin 40 mg daily for 7 days | THR, TKR HFS | Yes; outcomes taken from RCTs | Yes; data from Norwegian national sources | Yes | Yes |
Wolowacz 2009 | THR Dabigatran 220 mg daily versus enoxaparin 40 mg daily for 28-35 days TKR Dabigatran 220 mg daily for versus enoxaparin 40 mg daily 6-10 days | THR, TKR | Yes; outcomes taken from RCTs | Yes; data from UK national sources | Yes | Yes |
McCullagh, 2009 | THR Dabigatran 220 mg daily for 35 days versus rivaroxaban 10 mg daily for 35 days versus enoxaparin 40 mg daily for 14 days TKR Dabigatran 220 mg daily for 14 days versus rivaroxaban 10 mg daily for 10 days versus enoxaparin 40 mg daily for 10 days | THR, TKR | Yes; outcomes taken from RCTs | Yes; data from literature and Irish national sources | Yes | Yes |
Pechevis, 2000 | Yes | N/R | No | Yes | Yes | Yes |
Lloyd, 2001 | Yes | N/R | No | Yes | Yes | Yes |
Lamy, 2002 | Yes | N/R | No | Yes | Yes | Yes |
Offord, 2003 | Yes | N/R | No | Yes | Yes | Yes |
Schadlich, 2006 | Incompletely | N/R | No | Yes | Yes | Yes |
Drummond, 1994 | Incompletely | N/R | No | Yes | Yes | Likely |
Hawkins, 1997 | Yes | N/R | No | Yes | Yes | Yes |
Marchetti, 1999 | Incompletely | N/R | No | Yes | Yes | Yes |
Etchells, 1999 | Yes | N/R | No | Yes | Yes | Yes |
McGarry, 2004 | Incompletely | N/R | No | Yes | Yes | Yes |
Article
|
Were incremental costs and outcomes measured?
|
Do incremental costs and outcomes differ between subgroups?
|
Does allowance for uncertainty change results?
|
Are prophylaxis benefits worth the harm and costs?
|
Generalizability: could other patient populations expect similar outcomes?
|
Generalizability: could other patient populations expect to experience similar costs?
|
Heerey, 2005 | Incompletely | N/R | No | Yes | Yes | Likely |
Deitelzweig, 2008 | Yes | N/R | No | Yes | Yes | Likely |
Wade, 2008 | Yes | Yes | Yes | Yes | Yes | Yes |
O'Brien, 1994 | Yes | N/R | No | Yes | Yes | Yes |
Menzin, 1995 | Yes | N/R | No | Yes | Yes | Yes |
Hull, 1997 | Yes | N/R | No | Yes | Yes | Yes |
Hawkins, 1998 | Yes | N/R | No | Yes | Yes | Yes |
Francis, 1999 | Yes | Yes | Yes | Likely | Yes | Yes |
Botteman, 2002 | Incompletely | N/R | No | Yes | Perhaps | Yes |
Nerurkar, 2002 | Incompletely | N/R | No | Yes | Perhaps | Yes |
Levin, 2001 | Incompletely | N/R | No | Yes | Yes | Likely |
Caprini, 2002 | Yes | Yes | No | Yes | Yes | Likely |
Were incremental costs and outcomes measured?
|
Do incremental costs and outcomes differ between subgroups?
|
Does allowance for uncertainty change results?
|
Are prophylaxis benefits worth the harm and costs?
|
Generalizability: could other patient populations expect similar outcomes?
|
Generalizability: could other patient populations expect to experience similar costs?
| |
Honorato, 2004 | Yes | N/R | No | Yes | Yes | Yes |
Wade, 2001 | Incompletely | N/R | No | Yes | Yes | Yes |
Gordois, 2003 | Yes | N/R | No | Yes | Yes | Yes |
Wade, 2003 | Yes | N/R | No | Yes | Yes | Yes |
Annemans, 2004 | Yes | N/R | No | Yes | Yes | Yes |
Attanasio, 2001 | Yes | N/R | No | Yes | Yes | Yes |
Szucs, 2003 | Yes | Yes | No | Yes | Yes | Yes |
Sullivan, 2004 | Yes | Yes | No | Yes | Yes | Yes |
Dranitsaris, 2004 | Yes | N/R | No | Yes | Yes | Yes |
Spruill, 2004 | Yes | N/R | No | Yes | Yes | Yes |
Spruill, 2004 | Yes | N/R | No | Yes | Yes | Yes |
Wade, 2004 | Yes | N/R | No | Yes | Yes | Yes |
Bjorvatn, 2005 | Yes | Yes | No | Yes | Yes | Yes |
Wolowacz 2009 | Yes | Yes | No | Yes | Yes | Yes |
McCullagh 2009 | Yes | Yes | No | Yes | Yes | Yes |
Study perspectives, time horizon, and funding
Study quality
Cost and effect estimates
Low Molecular Weight Heparins versus Placebo
Low-molecular-weight heparins versus placebo | ||||||
---|---|---|---|---|---|---|
Reference | Patient population | Incremental cost (USD) | Incremental effects (VTE avoided or life-years or QALYS gained) | ICER (USD/VTE event avoided or life-years or QALYS gained) | Bleeding complications | Most economically attractive drug |
*Pechevis, 2000 | Medical | Net saving (value not reported) per 1,000 patients with enoxaparin | 94 DVT/PE avoided, four lives (estimated 12 life-years) gained, per 1,000 patients with enoxaparin | Enoxaparin dominant | Not reported | Enoxaparin |
Lloyd, 2001 | Medical | $20,680 per 1,000 patients with enoxaparin | 20 VTE events avoided per 1,000 patients with enoxaparin | $1, 034 per VTE avoided with enoxaparin | Six more major bleeding events per 1,000 patients with enoxaparin | Enoxaparin |
*Lamy, 2002 | Medical | $1, 910 per 1,000 patients in tertiary care setting with enoxaparin | 2.3% fewer VTE events with enoxaparin | $83 per VTE avoided with enoxaparin | Not reported | Enoxaparin |
*Offord, 2004 | Medical | Net saving ($26,478) per 1,000 patients with enoxaparin | 14 VTE events and 3.5 deaths avoided per 1,000 patients with enoxaparin | Enoxaparin dominant | Not reported | Enoxaparin |
*Schaldich, 2006 | Medical | $44,665 per 1,000 patients with enoxaparin | 26 VTE events avoided per 1,000 patients with enoxaparin | $1, 711 per VTE avoided with enoxaparin | Not reported | Enoxaparin |
Low-molecular-weight heparins versus unfractionated heparin
| ||||||
Reference
|
Patient population
|
Incremental cost (USD)
|
Incremental effects (VTE avoided or life-years or QALYS gained)
|
ICER (USD/VTE event avoided or life-years or QALYS gained)
|
Bleeding complications
|
Most economically attractive drug
|
*Drummond, 1994, enoxaparin | HFS | Net saving ($43,609) per 1,000 patients with enoxaparin | Four deaths avoided per 1,000 patients with enoxaparin | Enoxaparin dominant | Not reported | Enoxaparin |
*Hawkins, 1997, enoxaparin | THR | $57,972 per 1,000 patients with enoxaparin | 47 DVT events avoided per 1,000 patients with enoxaparin | $1, 180 per VTE event avoided with enoxaparin | Not reported (implied enoxaparin increased bleeding risk) | Enoxaparin |
Marchetti, 1999, enoxaparin | THR | Net saving ($90,000) per 1,000 patients with enoxaparin | 70 life-years gained per, 1000 patients with enoxaparin | Enoxaparin dominant | Not reported | Enoxaparin |
*Etchells, 1999, enoxaparin | Colorectal surgery | $180,641 per 1,000 patients with enoxaparin | 0 VTE events avoided with enoxaparin | UFH dominant | 12 additional major bleeding events with enoxaparin | UFH |
Lloyd, 2001, enoxaparin | Medical | Net saving ($850) per 1,000 patients with enoxaparin | 21 VTE events avoided per 1,000 patients with enoxaparin | Enoxaparin dominant | 18 fewer major bleeding events with Enoxaparin | Enoxaparin |
*Offord, 2003, enoxaparin | Medical | Net saving ($54,649) per 1,000 patients with Enoxaparin | 20.5 VTE events and 0.5 deaths avoided per 1,000 patients with enoxaparin | Enoxaparin dominant | Not reported | Enoxaparin |
*McGarry, 2004, enoxaparin | Medical | $14,459 per 1,000 patients with enoxaparin | 10 VTE events and 4.4 deaths avoided per 1,000 patients with enoxaparin | $1, 445 per VTE event avoided, and $10,360 per death avoided with enoxaparin | 2.7% fewer bleeding events, 0.9% fewer episodes of HIT | Enoxaparin |
*Schadlich, 2006, enoxaparin | Medical | Net saving ($46,499) per 1,000 patients with Enoxaparin | N/R | Enoxaparin dominant | 7.7 fewer major bleeding episodes with enoxaparin | Enoxaparin |
*Deitelzweig, 2008 | Medical | Net saving ($339,361) per 1,000 patients with enoxaparin | 11 VTE events, three deaths avoided per 1,000 patients with enoxaparin | Enoxaparin dominant | Five major bleeding events, four episodes of HIT avoided per 1,000 patients with enoxaparin | Enoxaparin |
Wade, 2008, enoxaparin | Gynecology oncology Surgery | Net saving ($36,197) per 1,000 patients with enoxaparin | Eight DVTs, 18 PE events avoided per 1,000 patients with enoxaparin | Enoxaparin dominant | 21 additional major bleeding events per 1,000 patients with enoxaparin | Enoxaparin |
*Lloyd, 1997, nadroparin | Orthopedics | Net savings ($192,000) per 1,000 patients with enoxaparin | 50 VTE events avoided per 1,000 patients with enoxaparin | Enoxaparin dominant | Not reported | Nadroparin |
General surgery | Net savings ($33,000) per 1,000 patients with enoxaparin | Nine VTE events avoided per 1,000 patients with enoxaparin | Nadroparin dominant | Not reported | Nadroparin | |
Heerey, 2005, dalteparin | General surgery | $473,000 per 1,000 patients with dalteparin | 21 QALYs per 1,000 patients with dalteparin | $20,337/QALY gained with dalteparin | Not reported | Dalteparin |
Low-molecular-weight heparins versus warfarin
| ||||||
Reference
|
Patient population
|
Incremental cost (USD)
|
Incremental effects (VTE avoided or life-years or QALYS gained)
|
ICER (USD/VTE event avoided or life-years or QALYS gained)
|
Bleeding complications
|
Most economically attractive drug
|
*O'Brien, 1994, enoxaparin | THR | $133,571 per 1,000 patients with LMWH | Five VTE events, 0.4 deaths avoided per 1,000 patients with LMWH | $26,711 per VTE event avoided, $334,055 per death avoided, $32,158 per life-year gained with LMWH | Not reported | LMWH |
*Menzin, 1995, enoxaparin | THR | $69,659 per 1,000 patients with LMWH | 20.1 VTE events and 4.3 deaths avoided per 1,000 patients with LMWH | $3,466 per VTE avoided, $16,200 per additional death avoided | Not reported | LMWH |
*Hull, 1997, tinzaparin | TKR, THR | Net saving ($52,690) per 1,000 patients with LMWH | 60 VTE events avoided per 1,000 patients with LMWH | LMWH dominant | 2.2% increase in major bleeding events with LMWH | LMWH |
*Hawkins, 1998, enoxaparin | TKR | $126,766 per 1,000 patients with LMWH | 145 VTE events avoided per 1,000 patients with LMWH | $874 per VTE event avoided with LMWH | 0.3% increased risk of major bleeding event with LMWH | LMWH |
*Francis, 1999 | THR | Net saving ($153,000) per 1,000 patients treated with LMWH | 112 VTE events avoided per 1,000 patients with LMWH | LMWH dominant | 62 more patients with bleeding event with LMWH | LMWH |
*Botteman, 2002, enoxaparin | THR | $154,000 per 1,000 patients with LMWH | 77 DVTs avoided per 1,000 patients, 40 QALYs gained per 1,000 patients with LMWH | $2013 per DVT avoided, $40,169 per death avoided, $4349 per QALY gained with LMWH | Not reported | LMWH |
Nerurkar, 2002, enoxaparin | TKR | Net saving ($1, 054,000) per 1,000 patients with LMWH | Seven deaths avoided per 1,000 patients with LMWH | LMWH dominant | Not reported | LMWH |
*Caprini, 2002 | THR | $110,235 per 1,000 patients with LMWH | 5.8 VTE events avoided per 1,000 patients with LMWH | $19,006 per VTE event avoided with LMWH | Not reported | LMWH |
Comparison of low-molecular-weight heparins and other agents
| ||||||
Reference
|
Patient population
|
Incremental cost (USD)
|
Incremental effects (VTE avoided or life-years or QALYS gained)
|
ICER (USD/VTE event avoided or life-years or QALYS gained)
|
Bleeding complications
|
Most economically attractive drug
|
Levin, 2001, desirudin versus enoxaparin | THR | $72,000 per 1,000 patients | 19.1 life-years gained per 1,000 patients with desirudin | $3,794 per life-year gained | Not reported | Desirudin |
*Honorato, 2004, bemiparin versus enoxaparin | TKR | Net savings ($227,000) per 1,000 patients with bemiparin | 42 VTE events avoided per 1,000 patients with bemiparin | Bemiparin dominant | Not reported | Bemiparin |
*Attanasio, 2001, dermatan sulfate versus UFH 5,000 U, 3 times daily | Surgical cancer | Net saving ($53,000) per 1,000 patients with dermatan sulfate | 70 DVTs avoided and 3.1 lives gained per 1,000 patients with dermatan sulfate | Dermatan sulfate dominant | Five additional major bleeding events with dermatan sulfate | Dermatan sulfate |
Heerey, 2005, dalteparin 2,500 U versus dalteparin, 5,000 U | Abdominal surgery | $477,000 per 1,000 patients with dalteparin | 18 QALYs per 1,000 patients with dalteparin | $24,357/QALY gained with dalteparin | Not reported | Dalteparin 5,000 U |
Wade, 2001, tinzaparin versus enoxaparin | Spinal cord injury | $223,259 per 1,000 patients with enoxaparin | Not reported | Not reported | Not reported | Not reported |
Fondaparinux versus enoxaparin
| ||||||
Reference
|
Patient population
|
Incremental cost (USD)
|
Incremental effects (VTE avoided or life-years or QALYS gained)
|
ICER (USD/VTE event avoided or life-years or QALYS gained)
|
Bleeding complications
|
Most economically attractive drug
|
*Gordois, 2003 | THR, TKR, HFS | $10,000 per 1,000 patients by discharge from hospital with fondaparinux | 11 VTE events, 1.9 deaths avoided per 1,000 patients by discharge from hospital with fondaparinux | $1, 077 per VTE event avoided and $5,317 per death avoided with fondaparinux | Not reported | Fondaparinux |
*Lundkvist, 2003 | THR, TKR, HFS | Net saving ($59,000) per 1,000 patients with fondaparinux | 17.9 VTE events, 2.6 deaths avoided per 1,000 patients (average among three conditions) with fondaparinux | Fondaparinux dominant | Not reported | Fondaparinux |
Wade, 2003, enoxaparin, 30 mg twice daily enoxaparin, 40 mg once daily | THR | Net savings ($168,382) per 1,000 patients with enoxaparin | Three VTE events per 1,000 patients with enoxaparin | Enoxaparin dominant | 27 more bleeding episodes per 1,000 patients with fondaparinux compared with twice-daily enoxaparin Six more bleeding episodes per 1,000 patients with enoxaparin once daily compared with fondaparinux | Enoxaparin twice daily |
Annemans, 2004 | THR, TKR, HFS | $2,800 per 1,000 patients with fondaparinux | 17.7 VTE events per 1,000 patients with fondaparinux | $158 per VTE event avoided; $104 per death avoided with fondaparinux | 1.6 more bleeding episodes per 1,000 patients with fondaparinux | Fondaparinux |
*Dranitsaris, 2004 | THR, TKR, HFS | Net saving ($50,000) per 1,000 patients with fondaparinux | 16 VTE avoided per 1,000 patients with fondaparinux | Fondaparinux dominant | 10 more major bleeding events per 1,000 patients with fondaparinux | Fondaparinux |
Spruill, 2004 | TKR (2002 USD) | Net saving ($43,549) per 1,000 patients with fondaparinux | 36 VTE events avoided per 1,000 patients with fondaparinux | Fondaparinux dominant | 10 more major bleeds and three more minor bleeding events per 1,000 patients with fondaparinux | Fondaparinux |
Spruill, 2004 | THR (2002 USD) | Net saving ($18,898) per 1,000 patients with fondaparinux | 20 VTE events avoided per 1,000 patients with fondaparinux | Fondaparinux Dominant | 19 more major bleeding events per 1,000 patients with fondaparinux | Fondaparinux |
Wade, 2004 | HFS | $21,171 per 1,000 patients with fondaparinux | 34 VTE events avoided per 1,000 patients with fondaparinux | $623 per VTE avoided, $32,144 per QALY gained with fondaparinux | Approximately 20% increased bleeding costs for fondaparinux | Fondaparinux |
*Sullivan, 2004 | THR, TKR, HFS | Net savings ($67,000) per 1,000 patients treated with fondaparinux | 3.7 VTE events avoided per 1,000 patients with Fondaparinux | Fondaparinux dominant | Two more bleeding events per 1000 patients with Fondaparinux | Fondaparinux |
*Szucs, 2005 | THR, TKR, HFS | Net savings ($18,153) per 1,000 patients treated with fondaparinux | 8.1 VTE events avoided per 1,000 patients with fondaparinux | Fondaparinux dominant | 1.6 more bleeding events per 1,000 patients with fondaparinux | Fondaparinux |
*Bjorvatn, 2005 | THR, TKR, HFS | $53,553 per 1,000 patients treated with fondaparinux | 7.2 VTE events avoided per 1,000 patients with fondaparinux | $753 per VTE avoided, $6,782 per death avoided with fondaparinux | Two more bleeding events per 1,000 patients treated with fondaparinux | Fondaparinux |
Dabigatran versus rivaroxaban and low-molecular-weight heparins
| ||||||
Wolowacz, 2009 | THR | THR Net savings ($103,050) per 1,000 patients treated with dabigatran | Two VTEs avoided, eight life-years, six QALYs gained per 1,000 patients treated with dabigatran | Dabigatran dominant | Five additional major bleeding events, two episodes HIT avoided per 1,000 patients treated with dabigatran | Dabigatran |
TKR | Net savings ($8,162) per 1,000 patients treated with dabigatran | Four VTEs avoided, 9 life-years, 7 QALYs gained per 1,000 patients treated with dabigatran | Dabigatran dominant | Six additional major bleeding events, two episodes HIT avoided per 1,000 patients treated with dabigatran | ||
McCullagh, 2009 | THR | Net savings ($24,104) per 1,000 patients treated with rivaroxaban | 7 Life-years, 10 QALYs gained per 1,000 patients with rivaroxaban | Rivaroxaban dominant | Not reported | Rivaroxaban |
TKR | Net savings ($213,452) per 1,000 patients treated with rivaroxaban | 7 Life-years, 12 QALYs gained per 1,000 patients with rivaroxaban | Rivaroxaban dominant |
Unfractionated Heparin versus Low Molecular Weight Heparins
Warfarin versus Low-Molecular-Weight Heparins
Low-Molecular-Weight Heparins versus One another, and Other Comparisons
Fondaparinux versus Low Molecular Weight Heparins
Dabigatran and Rivaroxaban versus Low Molecular Weight Heparins
Sponsorship and Economic Comparisons
Discussion
Conclusion
Key messages
-
Low-molecular-weight heparins appear to be the most economically attractive strategy for venous thromboembolism prevention among the majority of medical and surgical patients, whereas fondaparinux is more economically attractive for orthopedic patients.
-
However, approximately two thirds of all evaluations were directly funded by the manufacturer of the new drug.
-
Such drugs were more likely to be found economically attractive in comparison to other strategies.
-
Limited opportunity for peer-reviewed and independent funding for economic evaluations may lead to reliance on industry sponsorship and bias in this field.